Emerging drugs for diffuse large B-cell lymphoma

Expert Review of Anticancer Therapy

Volumn 15, Issue 4, 2015, Pages 439-451

  Mondello, Patrizia ^a,b   Younes, Anas ^b  

^a UNIVERSITY OF MESSINA   (Italy)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Bcl 2; bromodomain; DLBCL; HDAC; ibrutinib; lenalidomide; monoclonal antibodies; MYC; PI3K

Indexed keywords

BLINATUMOMAB; CARBOPLATIN; CISPLATIN; COLTUXIMAB RAVTANSINE; COPANLISIB; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; DUVELISIB; ETOPOSIDE; EVEROLIMUS; FLUDARABINE; IDELALISIB; IFOSFAMIDE; LENALIDOMIDE; LYMPHOCYTE ANTIGEN RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; NIVOLUMAB; OBINUTUZUMAB; OFATUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PIDILIZUMAB; PINATUZUMAB VEDOTIN; POLATUZUMAB VEDOTIN; PREDNISOLONE; PROGRAMMED DEATH 1 RECEPTOR; RITUXIMAB; UNINDEXED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT;

ANEMIA; ANTINEOPLASTIC ACTIVITY; BLURRED VISION; BONE MARROW SUPPRESSION; CANCER IMMUNOTHERAPY; CREATININE BLOOD LEVEL; DRUG FATALITY; EYE TOXICITY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; LARGE CELL LYMPHOMA; MONOTHERAPY; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ANIMAL; DRUG DESIGN; GENE EXPRESSION REGULATION; GENETICS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROGNOSIS;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MOLECULAR TARGETED THERAPY; PROGNOSIS;

EID: 84925622568     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2015.1009042     Document Type: Review

References (98)

1. Michallet AS, Coiffier B. Recent developments in the treatment of aggressive non-Hodgkin lymphoma. Blood Rev 2009;23:11-23
2. Ziepert M, Hasenclever D, Kuhnt E, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28:2373-80
3. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-11
4. Müller C, Murawski N, Wiesen MH, et al. The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood 2012;119:3276-84
5. Alduaij W, Illidge TM. The future of anti-CD20 monoclonal antibodies: are we making progress? Blood 2011;117: 2993-3001
6. Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 2004;103:2738-43
7. Mössner E, Brünker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010;115:4393-402
8. Morschhauser FA, Cartron G, Thieblemont C, et al. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. J Clin Oncol 2013;31: 2912-19
9. A Study of Obinutuzumab (RO5072759) in Combination With CHOP Chemotherapy Versus MabThera/Rituxan (Rituximab) With CHOP in Patients With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA). Available from: https://clinicaltrials.gov/ct2/results?term=NCT01287741&Search=Search
10. Czuczman MS, Gregory SA. The future of CD20 monoclonal antibody therapy in B-cell malignancies. Leuk Lymphoma 2010;51:983-94
11. Cillessen SAGM, Mackus WJM, Castricum KCM, et al. Chemotherapy-refractory diffuse large B-cell lymphomas (DLBCL) are effectively killed by Ofatumumab-induced complementmediated cytoxicity. Blood 2007;110:2346
12. Coiffier B, Radford J, Bosly A, et al. A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma. Br J Haematol 2013;163:334-42
13. Matasar MJ, Czuczman MS, Rodriguez MA, et al. Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma. Blood 2013;122:499-506
14. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28:4184-90
15. Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma. Available from: https://clinicaltrials.gov/ct2/results?term=NCT01014208&Search=Search
16. Mølhøj M, Crommer S, Brischwein K, et al. CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis. Mol Immunol 2007;44:1935-43
17. Viardot A, Goebeler M, Nopponey R, et al. Blinatumomab monotherapy shows efficacy in patients with relapsed diffuse large B cell lymphoma. Blood 2011;188:1637
18. Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL). Available from: https://clinicaltrials.gov/ct2/results?term=NCT01741792&Search=Search
19. Viardot A, Goebeler M, Pfreundschuh M, et al. Open-label phase 2 study of the bispecific T-cell engager (BiTE) blinatumomab in patients with relapsed/refractory diffuse large b-cell lymphoma. Blood 2013;122:1811
20. Armand P, Nagler A, Weller EA, et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol 2013;31: 4199-206
21. Lesokhin AM, Ansell SM, Armand P, et al. Preliminary results of a phase i study of nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies. Blood 2014;124:21s(Suppl); abstr 291
22. Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139). Available from: https://clinicaltrials.gov/ct2/results?erm=NCT02038933&Search=Search
23. Polson AG, Williams M, Gray AM, et al. Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma. Leukemia 2010;24:1566-73
24. Morschhauser F, Flinn I, Advani RH, et al. Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin (PoV) or pinatuzumab vedotin (PiV) plus rituxumab (RTX) in patients (Pts) with relapsed/refractory (R/R) non Hodgkin lymphoma (NHL). J Clin Oncol 2014;32:5s(Suppl); abstr 8519
25. Lutz RJ, Zuany-Amorim C, Vrignaud P, et al. Preclinical evaluation of SAR3419 (huB4-DM4), an anti-CD19-maytansinoid immunoconjugate, for the treatment of B-cell lymphoma. Proc Am Assoc Cancer Res 2006;47:3731
26. Younes A, Kim S, Romaguera J, et al. Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. J Clin Oncol 2012;30:2776-82
27. Trneny M, Verhoef G, Dyer M JS, et al. Starlyte phase II study of coltuximab ravtansine (CoR, sar3419) single agent: clinical activity and safety in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL; NCT01472887). J Clin Oncol 2014;32:5s (Suppl); abstr 8506
28. Coiffier B, Thieblemont C, de Guibert S, et al. Phase II study of anti-CD19 antibody drug conjugate (SAR3419) in combination with rituximab: clinical activity and safety in patients with relapsed/refractory diffuse large B-cell lymphoma (NCT01470456). Blood 2013;122:4395
29. Kochenderfer JN, Yu Z, Frasheri D, et al. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood 2010;116:3875-86
30. Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent b-cell malignancies can be effectively treated with autologous t cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 2014;pii: JCO.2014.56.2025. [Epub ahead of print]
31. Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19. Available from: https://clinicaltrials.gov/ct2/results?term=NCT01864889&Search=Search
32. Gandhi AK, Kang J, Naziruddin S, et al. Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly. Leuk Res 2006;30: 849-58
33. Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 2011;22:1622-7
34. Wang M, Fowler N, Wagner-Bartak N, et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia 2013;27: 1902-9
35. Yang Y, Shaffer AL 3rd, Emre NC, et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 2012;21:723-37
36. Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, et al. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer 2011;117: 5058-66
37. Nowakowski GS, LaPlant B, Macon WR, et al. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study. J Clin Oncol 2014;pii: JCO.2014.55.5714. [Epub ahead of print]
38. Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma. Available from: https://clinicaltrials.gov/ct2/results?term=NCT01856192&Search=Search
39. Efficacy of Lenalidomide in Combination With Subcutaneous (SC) Rituximab + miniCHOP in DLBCL Patients of 80 Years Old or More. Available from: https://clinicaltrials.gov/ct2/results?term=NCT02128061&Search=Search
40. A Phase Ib/II Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive (DLBCL and MCL) B-cell Lymphoma. Available from: https://clinicaltrials.gov/ct2/results?term=NCT01582776&Search=Search
41. Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL). Available from: https://clinicaltrials.gov/ct2/results?term=NCT01197560&Search=Search
42. Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma. Available from: https://clinicaltrials.gov/ct2/results?term=NCT02142049&Search=Search
43. Uddin S, Hussain AR, Siraj AK, et al. Role of phosphatidylinositol 3'- kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 2006;108:4178-86
44. Rodon J, Dienstmann R, Serra V, et al. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol 2013;10:143-53
45. Lannutti BJ, Meadows SA, Herman SE, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011;117:591-4
46. Kahl B BC, Byrd JC, Flinn WI, et al. Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110, in patients with relapsed or refractory non-hodgkin lymphoma. Blood 2010;116:1777
47. Winkler DG, Faia KL, DiNitto JP, et al. PI3K-d and PI3K-g inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol 2013;20:1364-74
48. Horwitz S, Flinn I, Patel M, et al. Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-d,g, in patients with relapsed/refractory lymphoma. J Clin Oncol 2013;31 (Suppl); abstr 8518
49. Liu N, Rowley BR, Bull CO, et al. BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110a and p110d activities in tumor cell lines and xenograft models. Mol Cancer Ther 2013;12:2319-30
50. Patnaik A, Ramanathan RK, Appleman LJ, et al. Phase I study of intravenous PI3K inhibitor bay 80-6946: preliminary activity in patients with relapsed non-hodgkin lymphoma (NHL) treated in an MTD expansion cohort. Blood 2012;120:3704
51. Dreyling M, Morschhauser F, Bron D, et al. Preliminary results of a phase II study of single agent bay 80-6946, a novel PI3K inhibitor, in patients with relapsed/refractory, indolent or aggressive lymphoma. Blood 2013;122:87
52. Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas. Available from: https://clinicaltrials.gov/ct2/results?term=NCT01660451&Search=Search
53. Wanner K, Hipp S, Oelsner M, et al. Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab. Br J Haematol 2006;134:475-84
54. Witzig TE, Reeder CB, LaPlant BR, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 2011;25:341-7
55. Xu ZZ, Wang WF, Fu WB, et al. Combination of rituximab and mammalian target of rapamycin inhibitor everolimus (RAD001) in diffuse large B-cell lymphoma. Leuk Lymphoma 2014;55: 1151-7
56. Barnes JA, Jacobsen E, Feng Y, et al. Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma. Haematologica 2013;98:615-19
57. Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy. Available from: https://clinicaltrials.gov/ct2/results?term=NCT00790036&Search=Search
58. Gauld SB, Dal Porto JM, Cambier JC. B cell antigen receptor signaling: roles in cell development and disease. Science 2002;296: 1641-2
59. Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010;463: 88-92
60. Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010;115: 2578-85
61. Buchner M, Baer C, Prinz G, et al. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia. Blood 2010;115:4497-506
62. Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer. Available from: https://clinicaltrials.gov/ct2/results?term=NCT01499303&Search=Search
63. Advani RH, Buggy JJ, Sharman J, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013;31:88-94
64. Wilson W, Gerecitano J, Goy A, et al. The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed/refractory de novo diff use large B-cell lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2 study. Blood 2012;120:1s(Suppl); abstr 686
65. Younes A, Thieblemont C, Morschhauser F, et al. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. Lancet Oncol 2014;15:1019-26
66. Davis RE, Brown KD, Siebenlist U, et al. Constitutive nuclear factor kappaB activity is re- quired for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001;194:1861-74
67. Rajkumar SV, Richardson PG, Hideshima T, et al. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 2005;23:630-9
68. Dunleavy K, Pittaluga S, Czuczman MS, et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 2009;113:6069-76
69. Ruan J, Martin P, Furman RR, et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol 2011;29:690-7
70. Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients. Available from: https://clinicaltrials. gov/ct2/results?term=NCT00931918&Search=Search
71. Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory DLBCL Patients Before High-Dose Chemotherapy BEAM With ASCT. Available from: https://clinicaltrials. gov/ct2/results?term=NCT01805557&Search=Search
72. Feasibility Study Of Adding Bortezomib to R-ICE Chemotherapy To Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Available from: https://clinicaltrials.gov/ct2/results?term=NCT01226849&Search=Search
73. Hanahan D & Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70
74. Gascoyne RD, Adomat SA, Krajewski S, et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997;90: 244-51
75. Hu S, Xu-Monette ZY, Tzankov A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood 2013;121:4021-31
76. Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008;68: 3421-8
77. Wilson WH, O'Connor OA, Czuczman MS, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010;11: 1149-59
78. Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013;19: 202-8
79. Bertino JR, Johnson-Farley N, Bhagavathi S. Studies of the combination of ABT-199, a BH3 mimetic that specially targets Bcl-2 in combination with chemotherapy and the proteasome inhibitor bortezomib in "double hit" lymphoma. J Clin Oncol 2014;32 (Suppl); abstr e19507
80. Davids MS, Seymour JF, Gerecitano JF, et al. Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses. J Clin Oncol 2014;32:5s(Suppl); abstr 8522
81. A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma. Available from: https://clinicaltrials.gov/ct2/results?term=NCT01594229&Search=Search
82. A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma. Available from: https://clinicaltrials.gov/ct2/results?term=NCT02055820&Search=Search
83. Geutjes EJ, Bajpe PK, Bernards R. Targeting the epigenome for treatment of cancer. Oncogene 2012;31:3827-44
84. Rosato RR, & Grant S. Histone deacetylase inhibitors: insights into mechanisms of lethality. Expert Opin Ther Targets 2005;9: 809-24
85. Mai A, Altucci l. Epdrugs to fight cancer: from chemistry to cancer treatment, the road ahead. Int J Biochem cell Biol 2009;41:199-213
86. Lindemann RK, Newbold A, Whitecross KF, et al. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci USA 2007;104:8071-6
87. O'Connor OA, Heaney ML, Schwartz L, et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 2006;24:166-73
88. Crump M, Coiffier B, Jacobsen ED, et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol 2008;19:964-9
89. Bhalla S, Balasubramanian S, David K, et al. PCI- 24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells. Clin Cancer Res 2009;15:3354-65
90. Dasmahapatra G, Lembersky D, Kramer L, et al. The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Blood 2010;115: 4478-87
91. Holkova B, Kmieciak M, Bose P, et al. Phase I trial of carfilzomib in combination with vorinostat (SAHA) in patients with relapsed/refractory b-cell lymphomas. Blood 2013;122:4375
92. Fournel M, Bonfils C, Hou Y, et al. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther 2008;7:759-68
93. Martell RE, Garcia-Manero G, Younes A, et al. Clinical development of MGCD0103, an isotype-selective HDAC inhibitor: pericarditis/pericardial effusion in the context of overall safety and efficacy. Blood 2009;114:4756
94. Crump M, Andreadis C Assouline SE, et al. A phase II study of single agent mocetinostat, an oral isotype-selective histone deacetylase (HDAC) inhibitor, in patients with diffuse large B-cell (DLBCL) and follicular (FL) lymphomas. J Clin Oncol 2013;31(Suppl); abstr 8535
95. Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011;146:904-17
96. Trabucco SE, Gerstein RM, Evens AM, et al. Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma. Clin Cancer Res 2014;pii: clincanres.3346.2013. [Epub ahead of print]
97. Emadali A, Rousseaux S, Bruder-Costa J, et al. Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers. EMBO Mol Med 2013;5:1180-95
98. Ceribelli M, Kelly PN, Shaffer AL, et al. Blockade of oncogenic IkB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors. Proc Natl Acad Sci USA 2014;111:11365-70